Table 2.

Univariate and multiple linear regressions showing the association of the use of bolus vitamin D3 supplements during or just before COVID-19 (independent variable) with the OSCI score for COVID-19 in acute phase (dependent variable), adjusted for participants' characteristics (n = 66).

	OSCI score for COVID-19 in acute phase
	Unadjusted model		Full-adjusted model
	Unadjusted β [95 % CI]	P-value	Full-adjusted β [95 % CI]	P-value
Bolus vitamin D3 supplementation during or just before COVID-19	−2.96 [-4.79;-1.12]	0.002	−3.84 [-6.07;-1.62]	0.001
Age	0.02 [-0.05;0.10]	0.563	0.04 [-0.05;0.12]	0.400
Female gender	−0.13 [-1.76;1.49]	0.870	0.36 [-1.41;2.12]	0.687
Number of drugs usually taken per day	−0.26 [-0.54;0.02]	0.070	−0.18 [-0.51;0.15]	0.273
GIR score	−0.28 [-0.86;0.30]	0.333	0.21 [-0.48;0.89]	0.617
Serum albumin concentration*	0.03 [-0.11;0.17]	0.647	−0.001 [-0.15;0.15]	0.993
Use of corticosteroids	2.41 [-0.36;5.20]	0.087	3.53 [0.30;6.75]	0.033
Use of hydroxychloroquine	1.83 [-2.11;5.76]	0.357	2.49 [-1.59;6.57]	0.226
Use of dedicated antibiotics	−0.22 [-1.59;1.14]	0.746	−0.56 [-2.21;1.10]	0.503
Hospitalization for COVID-19	1.09 [-1.75;3.92]	0.446	0.72 [-2.48;3.93]	0.652

β: coefficient of regression corresponding to a change in OSCI score for COVID-19 in acute phase (/8); CI: confidence interval; COVID-19: Coronavirus Disease 2019; GIR: Iso Resource Groups; OSCI: Ordinal Scale for Clinical Improvement of the World Health Organization; *: measured in preceding 6 months.